Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 84
Healthy Volunteers: f
View:
• Over 19 years old
• Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR \<45 / \<30 / \<15 or dialysis)
• Patients treated with a new generation drug eluting stent.
• Patients who signed consent form
Locations
Other Locations
Republic of Korea
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
RECRUITING
Seoul
Contact Information
Primary
Jung-Sun Kim, MD, PhD, FESC
KJS1218@yuhs.ac
82)-2)-2228-8457
Time Frame
Start Date: 2021-03-23
Estimated Completion Date: 2028-03-13
Participants
Target number of participants: 900
Treatments
Active_comparator: dual anti-platelet therapy at least 6 months
Experimental: dual anti-platelet therapy 3months or less
Related Therapeutic Areas
Sponsors
Leads: Yonsei University